Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
about
Critical appraisal of trastuzumab in treatment of advanced stomach cancerHER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practiceGastric biomarkers: a global reviewChanging strategies for target therapy in gastric cancerHER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the StomachMolecular classification of gastric cancer: Towards a pathway-driven targeted therapyHER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patients.Genomic profiling of submucosal-invasive gastric cancer by array-based comparative genomic hybridization.HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the LiteratureHER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.Causes and consequences of microsatellite instability in gastric carcinogenesis.Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review.HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancerTreatment options in patients with metastatic gastric cancer: current status and future perspectivesClinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma.New developments in the treatment of metastatic gastric cancer: focus on trastuzumabRecent advances in the HER2 targeted therapy of gastric cancerComparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily.In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma.Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis.Correlations of Human Epithelial Growth Factor Receptor 2 Overexpression with MUC2, MUC5AC, MUC6, p53, and Clinicopathological Characteristics in Gastric Cancer Patients with Curative Resection.Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients.Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer.Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancerHER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair.Prognostic Role of Primary Tumor Location in Non-Metastatic Gastric Cancer: A Systematic Review and Meta-Analysis of 50 Studies.Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial.Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer.Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinomaClinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapiesQuantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis.HER2-positive gastric cancer.Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes.Trastuzumab for gastric cancer.
P2860
Q24604411-84004820-46E0-4F79-96D8-7B6B42E02CE1Q26741253-1CBA9FDE-7A87-4F1E-90E8-CBE628BD7A6FQ26741859-7F5665D1-30C5-4744-A45B-FA14CADC4F12Q26774513-FEA67715-0279-4B93-97B3-01F985699C2FQ26780318-EE9FEB78-FEB6-4CD4-9B8E-7FA12765F512Q26798420-E80ABA3F-8699-4754-9413-E0D93368D2F6Q33925610-188C8DE5-569E-4AC9-8F7A-FA01AED04CA7Q33979826-6ACFA44D-1FA7-440F-99E1-C19D1A2D455DQ34223664-7A0E8604-A532-458C-B51D-0988E9D4DC8BQ34324291-03AF3ECA-F63F-4C9C-ADBF-CFA816C7C076Q34589660-AD4A5B1F-2375-43CC-8EB7-DEECDE586BB5Q34631121-5BFF0A5E-B24D-4DD5-8035-2F741A3A1322Q34638138-A2B290FB-40CF-4147-9280-D5169F9384F1Q34661367-A5901372-771D-4BFE-8069-ABC9DAB1EC3BQ34756800-F08CB1EF-4F30-47EE-8B00-3DF416518CF5Q34883258-95CCFCC9-FF9C-48FD-8051-6125CD8BE9F3Q34967104-23CA5B72-2378-4E8E-9263-314F4E376D15Q35006904-E5EEA98F-539F-4430-BAAD-2FBC5B3ECC19Q35047997-7B507BD1-2CA7-4EF8-8A76-398E586890C9Q35140953-E2336A84-9370-463E-884B-53EFF4181325Q35195417-8DE8162B-C068-46FE-95F5-F3666AEB8CE3Q35538755-903909EC-33EE-4D1D-86F3-2761F0574D98Q35594687-EBC14C81-DBEE-4B5C-BAF8-6E9C97D03627Q35642359-59BA123A-5555-40AA-84DD-99F129D4CFB7Q35681702-3C2A5CC2-5949-41A4-91EB-D3B103F08128Q36140927-AA86C187-09F3-430F-9756-577A5120A68AQ36220464-CA286159-9297-4F6A-85F4-A611BCBE1689Q36280791-5A9343CF-772B-428D-B8F2-99BF44744192Q36309934-28EF7548-FBDB-48E0-A7BD-DCCF7BA69A7EQ36630742-2C3C6B8C-F386-4EEC-8FD1-0A2F5C4DB3A6Q36648866-DE3848B9-AB27-48A5-84BE-0BE217A94C62Q36801203-7924B59A-2955-4A21-860A-CBDD355A866DQ36849324-B57310B0-C237-4609-AB47-7528544E6541Q36910400-92A62A54-F50F-40F0-8BE4-B157812C4347Q36999892-0B0AF10F-4075-4CBB-BC57-A1B231A7234EQ37241496-307725AD-818F-454E-9DDE-66603435963DQ37251780-0F48F8AF-0ED2-4544-9F99-7CF319F2D623Q37468290-42DE4A16-4D0A-4100-A9A2-0CDD0F001A9FQ37607824-636C67F6-E89C-4D2F-9BBF-F12C3872560FQ37633540-DFC47628-1F9F-4EF2-83F3-741A2C8006B2
P2860
Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Association of ERBB2 gene stat ...... in gastric carcinoma patients
@en
Association of ERBB2 gene stat ...... in gastric carcinoma patients.
@nl
type
label
Association of ERBB2 gene stat ...... in gastric carcinoma patients
@en
Association of ERBB2 gene stat ...... in gastric carcinoma patients.
@nl
prefLabel
Association of ERBB2 gene stat ...... in gastric carcinoma patients
@en
Association of ERBB2 gene stat ...... in gastric carcinoma patients.
@nl
P2093
P2860
P50
P356
P1476
Association of ERBB2 gene stat ...... in gastric carcinoma patients
@en
P2093
P Ferreira
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604885
P407
P50
P577
2009-01-20T00:00:00Z